Business Wire article link: Aadi Bioscience Initiates Rolling Submission of NDA to FDA for nab-sirolimus (ABI-009, FYARRO™) for the Treatment of Advanced Malignant PEComa Rolling submission of U.S. FDA New Drug Application initiated Long-term follow-up data released at ASCO 2020 for AMPECT study Independent reviewed ORR of 39% Long-term, durable ongoing responses ...
June 25, 2020admin
Business Wire article link: Aadi Bioscience Breakthrough Therapy nab-Sirolimus (ABI-009) Preliminary Data Released from the AMPECT Registration Trial in Advanced PEComa Highlights: Trial meets its Primary Endpoint with 39% ORR (95%CI 22%-58%) in patients with advanced PEComa – a rare sarcoma with no currently approved therapy First prospective clinical study in advanced ...
November 14, 2019admin
Business Wire article link: Aadi Bioscience Breakthrough Therapy nab-Sirolimus (ABI-009) Preliminary Data Released from the AMPECT Registration Trial in Advanced PEComa June, 3 2019, Aadi Bioscience, Inc. (Aadi), Aadi Bioscience, Inc (Aadi), a privately held clinical stage biopharmaceutical company, today released preliminary data on the ongoing nab-sirolimus (ABI-009) registration trial (AMPECT) for Advanced ...
June 3, 2019admin
March, 7 2019, Aadi Bioscience, Inc. (Aadi), For the first time in his life, Shanahan “Shanny” Dameral, 19, has a girlfriend. Soon, he’ll be graduating with a high school diploma and looking for his first job on the Kitsap Peninsula. What seems routine for many is a big deal for Dameral and ...
March 7, 2019admin
January, 3 2019, Aadi Bioscience, Inc. (Aadi), a clinical stage biopharmaceutical company focused on treating diseases driven by mTOR activation, today announced that its drug ABI-009 (sirolimus albumin-bound nanoparticles for injectable suspension) has received Breakthrough Therapy Designation status from the FDA for the indication of Advanced (metastatic or locally advanced) Malignant ...
January 3, 2019admin
October, 6 2017, The U.S. Food and Drug Administration today announced that it has awarded 15 new clinical trial research grants totaling more than $22 million over the next four years to boost the development of products for patients with rare diseases. These new grants were awarded to principal investigators from academia and ...
October 6, 2017admin
Aadi Bioscience, Inc. (Aadi), a clinical stage biopharmaceutical company focused on treating diseases driven by mTOR activation, today announced the completion of a $23 Million Series A round. The financing was led by Hermed Capital with participation from Celgene Corporation, Vivo Capital, Decheng Capital, the Helsinn Investment Fund and Star ...
May 8, 2017admin
Study to be conducted at major cancer centers across the US PACIFIC PALISADES, Calif. (Nov 2, 2015) -- AADi Bioscience, LLC, a clinical stage biopharmaceutical company focused on treating diseases driven by mTOR activation, today announced the initiation of its registration trial for advanced Perivascular Epithelioid Cell tumors (PEComa) with ABI-009, ...
November 2, 2015admin
By Michael Fitzhugh, Staff Writer Aadi LLC. A small new biotech company led by Abraxane (nab-paclitaxel) co-inventor Neil Desai, is in-licensing a once-shelved nanoparticle therapy from Celgene Corp. to develop it for oncology and cardiovascular indications. Celgene acquired the drug, ABI-009, in its 2010 acquisition of Abraxis Bioscience Inc. and retains ...
May 21, 2014admin
AADi Initiates NIH Funded Clinical Trial for Patients with Bladder Cancer PACIFIC PALISADES, Calif. (May 20, 2014) -- AADi, LLC, a clinical stage biopharmaceutical company focused on treating diseases uniquely suited for nanotechnology approaches, today announced the inlicensing of ABI-009 from Celgene Corporation (NASDAQ:CELG). ABI-009 is the nanoparticle albumin-bound (nab®) version ...
May 20, 2014admin